INT5906

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1982
Last Reported 2010
Negated 5
Speculated 2
Reported most in Abstract
Documents 125
Total Number 127
Disease Relevance 19.58
Pain Relevance 101.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transducer activity (Oprm1)
Anatomy Link Frequency
brain 12
neurons 7
dorsal horn 4
plasma 3
spinal 3
Oprm1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
opioid receptor 376 100.00 Very High Very High Very High
agonist 175 100.00 Very High Very High Very High
Opioid 168 100.00 Very High Very High Very High
mu opioid receptor 154 100.00 Very High Very High Very High
narcan 98 100.00 Very High Very High Very High
Enkephalin 96 100.00 Very High Very High Very High
antagonist 69 100.00 Very High Very High Very High
Analgesic 67 100.00 Very High Very High Very High
antinociception 41 100.00 Very High Very High Very High
Kinase C 17 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 13 99.96 Very High Very High Very High
Injury 22 99.92 Very High Very High Very High
Opiate Addiction 10 99.92 Very High Very High Very High
Urological Neuroanatomy 63 99.68 Very High Very High Very High
Neuropathic Pain 42 99.58 Very High Very High Very High
Nervous System Injury 19 99.54 Very High Very High Very High
Diabetes Mellitus 33 99.16 Very High Very High Very High
Hyperalgesia 30 99.16 Very High Very High Very High
Bordatella Infection 19 98.46 Very High Very High Very High
Epilepsy 3 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Chronic treatment with naltrexone appears to produce a region-specific downregulation of MOR-1 mRNA levels, which may be secondary to the naltrexone-induced increase in mu receptor binding.
Negative_regulation (downregulation) of MOR-1 mRNA
1) Confidence 0.59 Published 1995 Journal Brain Res. Bull. Section Abstract Doc Link 7583338 Disease Relevance 0.07 Pain Relevance 0.87
Loss of spinal mu-opioid receptor is associated with mechanical allodynia in a rat model of peripheral neuropathy.
Negative_regulation (Loss) of mu-opioid receptor in spinal associated with allodynia, narcan, peripheral neuropathy and opioid receptor
2) Confidence 0.59 Published 2006 Journal Pain Section Title Doc Link 16564625 Disease Relevance 1.18 Pain Relevance 1.41
Furthermore, [(3)H]naloxone binding indicated a lack of mu receptor downregulation in morphine-tolerant rat pups.
Negative_regulation (downregulation) of mu receptor associated with narcan and morphine
3) Confidence 0.59 Published 2007 Journal Brain Res. Section Abstract Doc Link 17300766 Disease Relevance 0 Pain Relevance 1.62
Chronic administration of morphine to pre- and postnatal rats produced a marked decrease in brain mu-opioid receptor density with-out change in receptor affinity.
Negative_regulation (decrease) of brain mu-opioid receptor in brain associated with opioid receptor and morphine
4) Confidence 0.59 Published 1988 Journal Brain Res. Section Abstract Doc Link 2841016 Disease Relevance 0 Pain Relevance 0.67
In the acute treatment, expression levels for the encoded mu-opioid receptor Oprm1, as detected by reverse transcription-polymerase chain reaction, were significantly decreased in the periaqueductal gray.
Negative_regulation (decreased) of Oprm1 associated with opioid receptor and central grey
5) Confidence 0.58 Published 2006 Journal Neuroscience Section Abstract Doc Link 16753266 Disease Relevance 0.26 Pain Relevance 0.63
Group 2 showed pronounce decreases in mu-opioid receptor density in different brain regions.
Negative_regulation (decreases) of mu-opioid receptor in brain associated with opioid receptor
6) Confidence 0.58 Published 1996 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 8816272 Disease Relevance 0.17 Pain Relevance 0.14
The decrease in mu-opioid receptor density was less marked in the group 1, 3 and 4.
Negative_regulation (decrease) of mu-opioid receptor associated with opioid receptor
7) Confidence 0.58 Published 1996 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 8816272 Disease Relevance 0.17 Pain Relevance 0.14
These data suggest that chronic blockade of the mu receptor with naloxone may induce a functional supersensitivity to the effects of mu- but not to those of kappa-agonists on the hypothalamus-pituitary-adrenocortical axis.
Negative_regulation (blockade) of mu receptor in pituitary associated with agonist and narcan
8) Confidence 0.58 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8396640 Disease Relevance 0 Pain Relevance 0.86
However, this chronic exposure decreased mu-receptor affinity in both fetal and maternal brain homogenates when determined on day 20 of pregnancy.
Negative_regulation (decreased) of mu-receptor in brain
9) Confidence 0.58 Published 1992 Journal Neurotoxicol Teratol Section Abstract Doc Link 1326078 Disease Relevance 0 Pain Relevance 0.63
Naloxone administered at a dose of 1 mg/kg i.v., which blocks all opioid receptors, or at a low dose of 1 microg/kg i.v., which selectively blocks the mu-opioid receptor, inhibited the anti-hyperalgesic effect of clomipramine and hence indicated that mu-opioid receptor is involved.
Negative_regulation (blocks) of mu-opioid receptor associated with hyperalgesia, narcan and opioid receptor
10) Confidence 0.58 Published 2003 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 12954814 Disease Relevance 0.36 Pain Relevance 1.02
Using RT-PCR we demonstrated a down-regulation of mu-opioid receptor mRNA by 62% after morphine exposure (P < 0.05).
Negative_regulation (down-regulation) of mu-opioid receptor mRNA associated with opioid receptor and morphine
11) Confidence 0.58 Published 2003 Journal Anesth. Analg. Section Abstract Doc Link 14570665 Disease Relevance 0.08 Pain Relevance 1.55
We show the development of behavioral tolerance and mu-opioid receptor mRNA down-regulation in the dorsal root ganglia in rats after chronic morphine treatment.
Negative_regulation (down-regulation) of mu-opioid receptor mRNA in dorsal root ganglia associated with tolerance, opioid receptor and morphine
12) Confidence 0.58 Published 2003 Journal Anesth. Analg. Section Abstract Doc Link 14570665 Disease Relevance 0.06 Pain Relevance 1.43
In the DG, the mu-opioid receptor density was reduced only in morphine-exposed but not in saline-exposed, TP-treated males compared with GNX males.
Negative_regulation (reduced) of mu-opioid receptor associated with opioid receptor and morphine
13) Confidence 0.58 Published 2003 Journal Hippocampus Section Abstract Doc Link 12836915 Disease Relevance 0 Pain Relevance 1.12
In the CA1, only morphine-exposed but not saline-exposed, hormone-treated females (EB, P, or EB+P) had a decrease in mu-opioid receptor density relative to OVX females.
Negative_regulation (decrease) of mu-opioid receptor associated with opioid receptor and morphine
14) Confidence 0.58 Published 2003 Journal Hippocampus Section Abstract Doc Link 12836915 Disease Relevance 0 Pain Relevance 0.97
In contrast, the enkephalin mRNA level was increased in the striatum, and mu-opioid receptor mRNA levels were markedly decreased in the globus pallidus after 7 days of haloperidol administration.
Negative_regulation (decreased) of mu-opioid receptor in striatum associated with opioid receptor and enkephalin
15) Confidence 0.58 Published 1994 Journal J. Neurochem. Section Abstract Doc Link 8035203 Disease Relevance 0 Pain Relevance 0.76
A significant decrease in the mu receptor density was found only in the frontal cortex of epileptic WAG/Rij rats.
Negative_regulation (decrease) of mu receptor in frontal cortex associated with epilepsy and urological neuroanatomy
16) Confidence 0.57 Published 1998 Journal Epilepsy Res. Section Abstract Doc Link 9477150 Disease Relevance 0.67 Pain Relevance 0.36
This attenuation may be due to decreased mu opioid receptor sensitivity or density resulting from chronic tricyclic antidepressant administration.
Negative_regulation (decreased) of mu opioid receptor associated with mu opioid receptor and tricyclic antidepressant
17) Confidence 0.57 Published 1990 Journal Pain Section Abstract Doc Link 2250923 Disease Relevance 0.08 Pain Relevance 0.62
In contrast, administration of the nonselective opioid receptor alkylating antagonist beta-chlornaltexamine (beta-CNA) over a similar range of doses was found to be nonselective for either delta radioligand, and produced greater inhibition of Oprm1 relative to Oprd1 binding, consistent with the nonselective pharmacological activity of this antagonist.
Negative_regulation (inhibition) of Oprm1 associated with antagonist and opioid receptor
18) Confidence 0.56 Published 2006 Journal Synapse Section Abstract Doc Link 16847946 Disease Relevance 0 Pain Relevance 0.60
These studies have shown that, after the reduction of a disulfide bond at or near the mu opioid binding site, this sulfhydryl group can be specifically alkylated, resulting in the affinity labeling of the mu opioid binding site.
Negative_regulation (reduction) of mu opioid binding site associated with opioid
19) Confidence 0.54 Published 1990 Journal Mol. Pharmacol. Section Abstract Doc Link 1688995 Disease Relevance 0 Pain Relevance 1.09
Moreover, we demonstrated that the selective blockade of mu-opioid receptor by cyprodime (CP) enhanced antiallodynic effect of SHU9119 as well as pronociceptive action of MTII, whereas the combined administration of mu receptor agonist (DAMGO) and SHU9119 significantly reduced the analgesic effect of those ligands.
Negative_regulation (blockade) of mu-opioid receptor associated with analgesic, agonist, opioid receptor and antiallodynic
20) Confidence 0.54 Published 2002 Journal Neuroreport Section Abstract Doc Link 12499847 Disease Relevance 0.76 Pain Relevance 1.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox